Talphera (NASDAQ:TLPH) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Talphera (NASDAQ:TLPH) in a research note published on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $4.00 target price on the stock.

Several other equities analysts have also issued reports on the company. Maxim Group raised Talphera to a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Talphera in a report on Tuesday, January 21st.

Talphera Price Performance

TLPH opened at $0.69 on Tuesday. The business has a fifty day moving average price of $0.65 and a 200 day moving average price of $0.81. The stock has a market capitalization of $11.82 million, a price-to-earnings ratio of -1.01 and a beta of 0.28. Talphera has a 12 month low of $0.50 and a 12 month high of $1.61.

Hedge Funds Weigh In On Talphera

A hedge fund recently bought a new stake in Talphera stock. Nantahala Capital Management LLC bought a new position in Talphera, Inc. (NASDAQ:TLPH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 1,992,519 shares of the company’s stock, valued at approximately $1,773,000. Nantahala Capital Management LLC owned 11.73% of Talphera at the end of the most recent reporting period. Institutional investors own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.